| Developer | Designation | Description | Development Status & Location - Indications |
|
EntreMed
Affiliate(s): · Roche Current as of: March 12, 2009 | Other Designation: MKC-1 (formerly R440 and Ro 31-7453) | MKC-1, a novel orally active bisindolylmaleimide, is a cell-cycle inhibitor and apoptosis inducer with broad antitumor activity. Administration Route: PO | Phase I (begin 10/88, completed 00) USA, phase I (closed 1/02) USA, phase I (begin 3/08, ongoing 3/09) USA - solid tumors, advanced or metastatic Phase II (begin 8/01, completed 9/02) USA, Europe (UK, Spain), phase II (begin 1/06, closed 6/08) USA; phase II (begin 01/06, closed 06/08) USA - breast cancer, advanced or metastatic Phase II (completed 8/02) USA, Germany, UK, Italy; phase I/II (begin 10/06, completed 11/08) USA (combination); phase I/II (begin 10/06, ongoing 06/08) USA (combination) - non-small cell lung cancer (nsclc), advanced, refractory Phase II (begin 9/01, completed 9/02) USA - colorectal cancer, refractory, recurrent or metastatic Phase I (begin 9/06, ongoing 6/07) USA; phase I (begin 7/07, ongoing 3/09) Canada - acute myeloid leukemia (AML), relapsed or refractory • hematologic malignancies, relapsed or refractory Phase II (begin 12/07, ongoing 3/09) USA - pancreatic cancer, recurrent or metastatic, inoperable Phase II (begin 1/08, closed 1/09) Canada - ovarian cancer, advanced, recurrent or refractory • endometrial cancer, advanced |